Vice President, Disease Area Leader-Neuromuscular Disease

J oin Us in Tackling Autoimmune Disease at Its Root At Vor, we believe science can do more than manage symptoms. It can change the course of disease. By advancing telitacicept, a first- and potentially best-in-class dual BAFF/APRIL inhibitor, we are silencing upstream survival signals and stopping downstream autoimmune cascades. Together, we are addressing disease at its root cause and rewriting what is possible for patients worldwide. When you join Vor, you’re not just working on a medicine. You’re part of a mission to redefine the future of autoimmune care. Why Work at Vor? Impact: Contribute directly to a medicine with best-in-disease Phase 3 results in myasthenia gravis and expansion into multiple autoimmune diseases. Growth: Be part of a rapidly scaling company with opportunities to grow your career in science, clinical development, commercial strategy, and beyond. Innovation: Work on a platform with potential beyond one indication — a therapy that has already shown consistent results across lupus, IgA nephropathy, and Sjögren’s syndrome. Belonging: Join a culture where every voice is heard, and where our shared mission unites us across functions and geographies. Vice President, Disease Area Leader – Neuromuscular Disease Reports to: Chief Medical Officer Position Summary The Vice President, Disease Area Leader – Neuromuscular Disease is the strategic and operational leader for late-stage clinical development in the company’s neuro-immunology portfolio. This executive owns the end-to-end development strategy, drives pivotal-stage execution, and ensures programs are positioned for regulatory approval and commercial readiness and launch. This role operates as a senior strategist, manager, and hands-on clinical leader, directly shaping study design, data interpretation, regulatory interactions, and cross-functional alignment. The VP, Disease Area Leader will also be the externally facing voice for the asset to medical and scientific community. Key Responsibilities Strategic Leadership · Define and lead the late-stage development strategy for neuroimmunology programs, ensuring clear differentiation and regulatory readiness. · Drive portfolio prioritization and scenario planning with a pragmatic, resource-conscious approach. · Serve as the company’s senior expert in neuro-immunology, integrating emerging science, competitive intelligence, and patient insights. Late-Stage Clinical Development · Lead design and execution of registration-enabling and planning for post-registrational studies, balancing scientific rigor with operational feasibility. · Provide senior medical oversight of clinical team members for ongoing trials, including safety review, data interpretation, and benefit-risk assessments. · Partner closely with Clinical Operations to troubleshoot issues, accelerate timelines, and ensure high-quality study conduct across a small, agile team. · Oversee development of statistical analysis plans, endpoint strategies, and data packages for regulatory and commercial use. Regulatory Strategy & Interactions · Contribute to global regulatory strategy for late-stage programs, including preparation of briefing documents, pivotal submissions, and labeling negotiations. · Lead clinical interactions with FDA, EMA, and other agencies, ensuring clear, evidence-based communication. · Anticipate regulatory risks and proactively develop mitigation strategies. Cross-Functional Leadership in a Lean Environment · Lead clinical and cross-functional development teams · Partner with Medical Affairs, HEOR, and Commercial to assure KOL engagement and align evidence generation with launch readiness and payer expectations. · Collaborate with CMC, Quality, and Manufacturing to ensure late-stage readiness and supply continuity for pivotal studies. · Represent the disease area at executive governance forums with crisp, data-driven recommendations. External Engagement · Build and maintain relationships with key opinion leaders, investigators, and pat